Elkfork Partners LLC Purchase Shares of 996,968 Johnson & Johnson (JNJ)

Elkfork Partners LLC Purchase Shares of 996,968 Johnson & Johnson (JNJ)

Elkfork Partners LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 996,968 shares of the company’s stock, valued at approximately $114,861,000. Johnson & Johnson accounts for about 3.8% of Elkfork Partners LLC’s portfolio, making the stock its 3rd largest position.

Several other hedge funds have also bought and sold shares of JNJ. Oliver Luxxe Assets LLC boosted its stake in Johnson & Johnson by 3.6% in the third quarter. Oliver Luxxe Assets LLC now owns 14,651 shares of the company’s stock worth $1,731,000 after buying an additional 512 shares during the last quarter. Stokes & Hubbell Capital Management LLC boosted its stake in Johnson & Johnson by 0.3% in the third quarter. Stokes & Hubbell Capital Management LLC now owns 89,666 shares of the company’s stock worth $10,592,000 after buying an additional 269 shares during the last quarter. Central Bank & Trust Co. boosted its stake in Johnson & Johnson by 0.7% in the third quarter. Central Bank & Trust Co. now owns 16,842 shares of the company’s stock worth $1,989,000 after buying an additional 114 shares during the last quarter. Nadler Financial Group Inc. boosted its stake in Johnson & Johnson by 2.2% in the third quarter. Nadler Financial Group Inc. now owns 8,595 shares of the company’s stock worth $1,015,000 after buying an additional 187 shares during the last quarter. Finally, Advisory Services Network LLC boosted its stake in Johnson & Johnson by 7.9% in the third quarter. Advisory Services Network LLC now owns 32,638 shares of the company’s stock worth $3,856,000 after buying an additional 2,403 shares during the last quarter. 65.30% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE:JNJ) opened at 124.55 on Friday. The stock has a market cap of $337.95 billion, a price-to-earnings ratio of 21.00 and a beta of 0.74. Johnson & Johnson has a 1-year low of $107.88 and a 1-year high of $129.00. The firm’s 50 day moving average price is $123.50 and its 200-day moving average price is $117.56.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.56 by $0.02. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. The company earned $18.10 billion during the quarter, compared to analysts’ expectations of $18.28 billion. During the same period last year, the company posted $1.44 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $7.04 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 14th. Shareholders of record on Tuesday, February 28th were issued a $0.80 dividend. The ex-dividend date was Friday, February 24th. This represents a $3.20 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 54.42%.

JNJ has been the subject of a number of recent analyst reports. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $115.95 price objective for the company. in a research report on Monday, December 12th. Jefferies Group LLC reissued a “hold” rating and issued a $107.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 20th. Credit Suisse Group AG reissued a “hold” rating on shares of Johnson & Johnson in a research report on Tuesday, December 20th. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $133.00 price objective on shares of Johnson & Johnson in a research report on Friday, January 6th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $124.09.

In other Johnson & Johnson news, VP Paulus Stoffels sold 22,000 shares of the stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $117.29, for a total value of $2,580,380.00. Following the completion of the transaction, the vice president now directly owns 127,650 shares of the company’s stock, valued at $14,972,068.50. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Related posts

Leave a Comment